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This registry-linkage study evaluates familial aggregation of cancer among relatives of a population-based series of early-onset
(≤40 years) cancer patients in Finland. A cohort of 376,762 relatives of early-onset cancer patients diagnosed between 1970
and 2012 in 40,538 families was identiﬁed. Familial aggregation of early-onset breast, colorectal, brain and other central
nervous system (CNS) cancer and melanoma was explored by standardized incidence ratios (SIR), stratiﬁed by relatedness.
Gender-, age- and period-speciﬁc population cancer incidences were used as reference. Cumulative risks for siblings and
offspring of the proband up to age ≤40 years were also estimated. Almost all early-onset cancers were sporadic (98% or more).
Among ﬁrst-degree relatives, SIR was largest in colorectal cancer (14, 95% conﬁdence interval 9.72–18), and lowest in
melanoma (1.93, 1.05–3.23). Highest relative-speciﬁc SIRs were observed for siblings in families, where also parent had
concordant cancer, 90 (43–165) for colorectal cancer and 29 (11–64) for CNS cancer. In spouses, all SIRs were at population
level. Cumulative risk of colorectal cancer by age 41 was 0.98% in siblings and 0.10% in population, while in breast cancer the
corresponding risks were 2.05% and 0.56%. In conclusion, early-onset cancers are mainly sporadic. Findings support high
familial aggregation in early-onset colorectal and CNS cancers. Familial aggregation in multiplex families with CNS cancers was
mainly attributed to neuroﬁbromatosis and in colorectal cancer to FAP- and HNPCC-syndromes. The pattern of familial
aggregation of early-onset breast cancer could be seen to support very early exposure to environmental factors and/or rare
genetic factors.
Background
The role of genetic and environmental factors in the develop-
ment of cancers remains an intriguing question and familial
aggregation of cancers provides possibilities to evaluate their
contribution. Familial clustering of cancer can be explained
either by inherited germline mutations or by shared exposure
to environmental factors and lifestyle, resulting in somatic
changes predisposing to cancer.
While major epidemiological evidence supports a signiﬁcant
causal role of environmental exposure in the risk of a wide range
of cancers,1,2 inherited mutations are more likely to contribute in
early age-at-onset cancers and respective family members.3
Despite the fact that more than 50 hereditary cancer syndromes
have been recognized,3 the known inherited mutations are evalu-
ated to contribute only about 4% of all childhood cancer cases4
and 5–10% of adult cancers.5,6
In order to evaluate familial risk, it is useful to assess the risk
using pedigree information by age-at-onset of cancers.7 Familial
aggregation of cancers using population-based data has been stud-
ied previously.8–10 In the analysis of the Swedish Family Cancer
Database,10 several familial cancer associations were established,
including cancers of the colon, breast, skin and nervous system,
when multiple same primary cancers were diagnosed in the same
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family. In a study investigating familial risks of the concordant can-
cers in parents and offspring by age at diagnosis, the highest cancer
risks were observed in offspring, whose parents were diagnosed of
a concordant cancer at earlier ages.11 In a large Nordic collabora-
tive study on familial melanoma, no difference in risk by morpho-
logical type was observed.12
The primary aim of the present study was to evaluate rela-
tive and cumulative risks of the concordant cancer in family
members of early-onset index cases called probands. We also
studied sibling risk stratiﬁed by parental cancer status and com-
pared early- vs. late age-at-onset of concordant cancers. By
exploring the pattern of familial aggregation in brain and other
central nervous system (CNS) cancers, colorectal and breast
cancer and melanoma of the skin, we aim to evaluate the con-
tribution of environmental and genetic components in the eti-
ology of these early-onset cancers.
Methods
Study design
Our study utilizes data of a prospective observational cohort of
376,762 relatives in 40,538 families of early-onset cancer patients
diagnosed at age ≤40 years in Finland between 1970 and 2012
(Table 1). The cohort was originally built to assess late effects in
the offspring of early-onset cancer survivors.13,14 The Finnish
Cancer Registry (FCR) and Population Information System
maintained by the Population Registry Centre, served as the data
sources. The FCR contains information on all diagnosed cancer
cases in Finland since 1953, including the unique personal ID
number and diagnostic details, such as tumor morphology. The
registry covers 96% of solid and 86% of nonsolid tumors.15 The
Population Information System is a registry of all permanent
Finnish residents and holds data on, for example, personal ID
number, family relations and date of birth and death, and
allows reliable identiﬁcation of family members. Links to sib-
lings are reliably available for individuals born after 1955, and
alive in 1967. Links to offspring, including legal children of
males, are nonsystematically available for children born after
1940, and systematically for children born after 1955, and
alive in 1967.
Families were identiﬁed by a proband, who was the ﬁrst can-
cer case in the family diagnosed at or under the age of 40 years
between January 1, 1970 and December 31, 2012, in Finland.
The family members (probands’ offspring, mother, father, sib-
lings, spouse and siblings’ offspring and siblings’ spouse) were
linked to the probands from the Population Information System.
We were not able to comprehensively and systematically retrieve
information on grandparents or other older second degree rela-
tives from the Population Information System.
Cancers were classiﬁed according to the International statistical
classiﬁcation of diseases and related health problems (ICD-10) as
follows: CNS (ICD10 codes C70–72, D32–33 and D42–43), color-
ectum (C18–20), breast (C50), melanoma (C43) and all other
malignancies. The study was approved by the National Institute for
Health andWelfare (Permit no. THL/1006/5.05.00/2017).
Follow-up and outcomes
The ascertainment of probands and family members, as well as
follow-up of cancer outcomes, is illustrated by a Lexis diagram
(Supporting Information Fig. S1). For all family members of the
proband, the follow-up begins either at the date of birth or
January 1, 1953. In order to avoid immortal time bias16 (period
of time when by study design cancer could not be diagnosed due
to the ascertainment), we did not consider family members of
the proband to be at risk of cancer between January 1, 1970, and
the date of diagnosis of the proband at 0–40 years of age. The
cancer-speciﬁc follow-up ended either at date of the cancer diag-
nosis, date of death or emigration, or December 31, 2016, which-
ever came ﬁrst. This leads to inclusion of certain time periods at
risk of family members prior to the date of diagnosis of the pro-
band: all ages from 1953 to 1970, and age ≥41 years from 1970
onwards. The SIR was estimated using all follow-up outside the
immortal periods.
Characteristics of cancer patients
The proportions of male and female probands, by primary site
and median age at diagnosis, are given in Supporting Infor-
mation Table S1. There were 17,852 (42%) males and 24,166
(58%) females among the probands. The median age at diag-
nosis for probands was 28 years for CNS cancer, 37 years for
breast cancer, 34 years for colorectal cancer and 33 years for
melanoma of the skin. The most prevalent early-onset cancer
diagnoses among probands were lymphomas and leukemias
(21%, 8,791 families). Even if hematological malignancies are
common in children, their distribution differs from that of young
adults (20–40 years) or all adults. In addition, the most recent
classiﬁcation of hematological malignancies into groups not fol-
lowing the traditional leukemia and lymphoma-division has to
be taken into account. Additionally, transformation of one
What’s new?
The tendency for certain cancer types to cluster in families generally is explained by shared environmental exposures or
inherited mutations. In particular, early-onset cancer, diagnosed between ages 0 and 40, is considered indicative of familial
factors. Here, investigation of cancer risk among more than 376,760 relatives of probands, or individuals with early-onset
cancer, shows that the likelihood of early-onset cancer affecting even just one other relative in addition to the proband is
exceedingly rare. Nearly all early-onset cancers in the study population were sporadic. Estimated cumulative risks observed for
speciﬁc cancers may prove useful in the context of genetic counseling.
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malignancy into something else, for example, myelodysplasias
into acute myeloid leukemias found in many adult cases needs
to be studied in more detail. We felt this complex group of dif-
ferent malignancies should be reported separately and are not
within the scope of the current study.
The next most prevalent diagnostic groups were breast cancer
(14%), CNS cancer (13%), melanoma (8%) and colorectal cancer
(5%). These cancer types were selected as examples of some of
the common early-onset cancer types, where familial aggregation
would be expected due to known predisposing genetic mutations
(such as hereditary nonpolyposis colorectal cancer [HNPCC],
familial adenomatous polyposis [FAP], BRCA1/2 gene mutations
and neuroﬁbromatosis [NF]).
More focused analysis was performed for siblings of the
proband, who had, in addition to the proband, at least one
parent diagnosed with a concordant cancer (later referred to
as multiplex families). For cancers in the multiplex families,
we checked the original clinical and pathology notiﬁcations
from the FCR and extracted any information concerning
selected cancer syndromes, FAP and HNPCC for multiplex
families with colorectal cancer, and NF for CNS cancers. Also,
any notes indicating BRCA1/2 gene mutation were extracted
from multiplex breast cancer families.
Statistical methods
Standardized incidence ratios (SIR) were used as measures of
familial aggregation as they compare sex-, age- and period-
speciﬁc cancer incidence among family members to that in
the population of Finland. SIRs were estimated for all ﬁrst-
degree relatives of the proband combined and for family
members separately by relatedness to the proband. Siblings of
the proband were further divided by parental cancer status:
siblings who had at least one parent diagnosed with a concor-
dant cancer, and siblings whose parents had not been diag-
nosed with the cancer in question. We also report SIRs for
cancers of the probands’ relatives diagnosed at ≤40 years
(early-onset) and at ≥41 years (late-onset) separately by relat-
edness. The estimates of SIRs were corrected for nonrandom
selection of families through the proband (ascertainment bias)
by excluding the proband from the analysis.7,17 Poisson
regression was used in the estimation of SIRs. In addition, we
estimated cumulative risks and expected cumulative risks from
0 to 41 years of age in offspring and siblings. In the estimation
of the cumulative risks, we considered only follow-up after the
diagnosis date of the proband. Details of the estimation of SIRs
and cumulative risks are given in the Supporting Information
Statistical Methods. All reported p values are two-sided, and to
control for overall type-1 error, we used Benjamini–Hochberg
procedure.
Our data had at least 80% power of ﬁnding a SIR of 1.7
among ﬁrst-degree relatives diagnosed at ≤40 years for cancers
of CNS, SIR 3.0 for colorectal cancer, SIR 1.7 for breast cancer
and SIR 2.2 for melanoma of the skin. Data on cancers are of
high coverage15 and are also complete for date of the
diagnosis and family members’ relatedness to the proband.
However, we are missing some parents of the probands. Infor-
mation on both parents was missing for 17.0% of the pro-
bands, whereas 6.4% had information on one parent only (see
chapter Study design on registry linkages).
Analysis was performed using the R software, version 3.5.0
(R project for Statistical Analysis) and packages Epi, version
2.30 and popEpi, version 0.4.5.
The data that support the ﬁndings of our study are avail-
able on request from the corresponding author. The data are
not publicly available due to privacy or ethical restrictions.
Results
The numbers and proportions of families, subjects and familial
cancers diagnosed at ≤40 years of age by primary site are pres-
ented in Table 1. Almost all, 98% or more, of the early-onset
cancers of the studied primary sites were sporadic. There were
78 families with at least one early-onset family member diag-
nosed with CNS cancer (1.4% of the families). Accordingly,
there were 39 families with at least one family member diag-
nosed with early-onset colorectal cancer (2.0%), 98 (1.8%) with
early-onset breast cancer and 26 (0.8%) cases of early-onset mel-
anoma of the skin. Additional tables for the numbers and pro-
portions of families, subjects, and familial cancers by primary
site for familial cancers at any age are shown in Supporting
Information Table S2, and for cancers diagnosed at ≥41 years in
Supporting Information Table S3. Age distributions of family
members at diagnoses and at the end of follow-up are presented
in Supporting Information Tables S4 and S5.
Relative risks of early-onset cancer among relatives of early-
onset proband
SIRs for early-onset cancers in family members diagnosed at
≤40 years of age are shown in Table 2. When considering all
ﬁrst-degree relatives of the proband combined, the SIRs for
early-onset familial cancers were elevated in all studied cancer
sites, ranging from 1.93 (95% CI 1.05–3.23) for melanoma of
the skin to 14 (9.72–18) for colorectal cancer.
The most elevated cancer risks for family members of the
proband were observed for early-onset colorectal cancer, where
the risk of cancers among all different ﬁrst-degree relatives was
over 10-fold compared to those expected, based on cancer inci-
dence in the national population.
Regarding CNS cancers, the SIR was elevated for offspring
(3.66, 2.32–5.49) and siblings (2.35, 1.50–3.49) of the proband.
Familial risk of early-onset female breast cancer was elevated
for offspring of the proband (SIR 3.61, 2.47–5.10) and siblings
(4.80, 3.47–6.47) of the proband, but SIR for the mother of the
proband did not reach statistical signiﬁcance (1.67, 0.72–3.30).
The SIR of skin melanoma was 1.93 (1.05–3.23) in all ﬁrst-
degree relatives of the proband combined, but none of the
SIRs for speciﬁc relatives were signiﬁcantly elevated.
SIR in siblings’ offspring was statistically increased only in
CNS cancer (1.86, 1.21–2.75).
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All SIRs for probands’ and their siblings’ spouses were at
population level, except for breast cancer, where the spouses’
risk was signiﬁcantly lowered. There was signiﬁcant heterogene-
ity (p < 0.001) in SIRs between ﬁrst-degree relatives (all com-
bined) and spouses for early-onset cancers of CNS, breast and
colorectum, but not for melanoma of the skin (p = 0.39). There
was some heterogeneity in SIRs between different ﬁrst-degree
relatives (p = 0.05) for breast cancer, but not for other cancers.
Cumulative risks for siblings and offspring
The cumulative sibling and offspring risks by the age of 40 for
all cancers studied are plotted in Figure 1. The cumulative risk
of colorectal cancer for the offspring of the proband with a
concordant cancer was 1.37% (95% CI 0.83–2.25%), and for
sibling 0.98% (0.58–1.64%), compared to the population
cumulative risk of 0.10%. Cumulative risk of CNS cancer for
offspring of CNS probands was 0.75% (0.49–1.17%) and pop-
ulation reference 0.24%. The corresponding cumulative risk
for siblings of the CNS proband was 0.53% (0.33–0.85%).
Cumulative risk of breast cancer for offspring of the proband
with breast cancer was 1.63% (1.15–2.31%) and the popula-
tion cumulative risk was 0.56%. The corresponding cumula-
tive risk for sibling was 2.05% (1.49–2.81%). Cumulative risk
of melanoma for offspring of the proband with melanoma
was 0.34% (0.15–0.76%) and accordingly for the sibling of the
proband 0.26% (0.12–0.57%), in contrast to population cumu-
lative risk of 0.18%.
Familial early-onset cancer risk by parental cancer status
Table 3 shows the early-onset familial relative risks (SIRs) of
the siblings of the proband by parental cancer status (concor-
dant cancer in at least one parent at any age). The highest SIR
was obtained for colorectal cancer in siblings with an affected
parent (SIR 90, 43–165). The SIR for colorectal cancer in siblings
of the proband without parental cancer was 5.29 (1.94–12).
Siblings of the proband with CNS cancer in families with
the concordant parental cancer were at considerably higher
familial risk of CNS cancer, with a SIR of 29 (11–64), com-
pared to healthy parent’s sibling (SIR 1.80, 1.06–2.84). Sib-
lings of the proband with a maternal breast cancer had a
SIR of 10 (4.85–19) and siblings without parental breast
cancer SIR 4.14 (2.85–5.81).
All CNS cancers in multiplex families with concordant
parental cancer were found in families with NF in at least
one family member diagnosed with CNS cancer (Table 3).
As for multiplex breast cancer families, no BRCA 1/2 gene
mutation carriers were reported in the clinical or pathology
notiﬁcations, but the contents of pathological reports are
limited up to 2014. Four of the siblings with early-onset
colorectal cancer and a concordant parental cancer were
either in families with FAP or HNPCC. The sibling SIR in
the remaining multiplex families with six sibling colorectal
cancers was 56 (21-122).Ta
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Early-onset vs. late-onset familial cancers
The increase in SIRs was more pronounced in ﬁrst-degree rel-
atives of the proband, who were diagnosed at an early age,
compared to cases diagnosed at age ≥41 years in all studied
cancers, except melanoma of the skin (Supporting Informa-
tion Table S6). The largest difference in familial SIRs between
diagnoses at ≤40 and at ≥41 years was observed for colorectal
cancer (p < 0.001 for homogeneity), where the familial SIR for
early-onset cancers in all ﬁrst-degree relatives of the proband
combined was 14 (9.72–18) and 2.11 (1.83–2.42) for cases
diagnosed at 41 years or later. The respective SIRs in CNS
cancers were 2.50 (1.88–3.27) and 1.32 (1.08–1.59, p < 0.001
for homogeneity). In breast cancer, the SIR for early-onset
disease in all ﬁrst-degree relatives of the proband combined
was 3.67 (2.92–4.55) and 1.67 (1.55–1.79) for diagnoses at
≥41 years (p < 0.001 for homogeneity). In skin melanoma,
there was no difference between early- and late-onset SIR of
the ﬁrst-degree relatives (p = 0.25). Regardless of age-at-onset,
the highest SIRs were observed for siblings of the proband,
when also at least either one of the parents was diagnosed
Table 2. Numbers of family members of the proband, number of observed cancer cases and standardized incidence ratios (SIR) for concordant
cancers in family members by relatedness to the proband, when also the family member was diagnosed at ≤40 years
Relatedness to the proband
Number of family
members of the
proband1
Number of
cancers2 Person-years
SIR for family
member for
concordant cancer3 (95% CI)
Brain and other CNS cancers4
First-degree relatives5 25,861 54 465,429 2.50 (1.88–3.27)
Offspring 5,829 23 126,523 3.66 (2.32–5.49)
Father 4,557 3 66,803 1.25 (0.26–3.66)
Mother 4,823 4 71,796 1.50 (0.41–3.84)
Sibling 10,652 24 200,307 2.35 (1.50–3.49)
Sibling’s offspring 14,439 25 278,142 1.86 (1.21–2.75)
Spouse 9,833 6 191,816 0.60 (0.22–1.31)
Breast cancer4
First degree relatives5 27,107 83 481,064 3.67 (2.92–4.55)
Offspring 9,443 32 214,269 3.61 (2.47–5.10)
Father 3,943 0 53,294 0.00 (0.00–314)
Mother 4,228 8 60,433 1.67 (0.72–3.30)
Sibling 9,493 43 153,068 4.80 (3.47–6.47)
Sibling’s offspring 16,098 14 315,018 1.44 (0.79–2.42)
Spouse 12,202 3 196,073 0.33 (0.07–0.97)
Colorectal cancer4
First degree relatives5 10,117 42 181,717 14 (9.72-18)
Offspring 3,227 16 71,764 13 (7.20–21)
Father 1,520 6 21,369 20 (7.21–43)
Mother 1,615 4 22,946 14 (3.72–35)
Sibling 3,755 16 65,638 13 (7.34–21)
Sibling’s offspring 6,228 4 122,967 1.97 (0.54–5.06)
Spouse 4,364 0 78,505 0.00 (0.00–2.43)
Melanoma4
First degree relatives5 15,399 14 265,724 1.93 (1.05–3.23)
Offspring 4,875 6 103,170 1.98 (0.73–4.31)
Father 2,520 1 36,247 2.29 (0.06–13)
Mother 2,666 0 38,673 0.00 (0.00–6.78)
Sibling 5,338 7 87,634 2.15 (0.86–4.43)
Sibling’s offspring 8,415 7 163,088 1.50 (0.60–3.10)
Spouse 6,338 5 107,597 1.25 (0.41–2.92)
1Includes all family members.
2Includes early-onset cancers in family members of the proband.
3SIR (95% CI) for concordant cancer in the family member of the proband.
4p-Value for homogeneity of the SIRs between first-degree relatives combined and spouses was p < 0.001 for cancers of the CNS, breast and colorectum,
and p = 0.39 for skin melanoma.
5Includes offspring, father, mother and siblings of the proband.
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with the concordant cancer, except in late-onset skin
melanoma.
Discussion
To the best of our knowledge, this is the ﬁrst study with a
population-based ascertainment focusing on familial aggrega-
tion of early-onset cancers. We found that even having one
other family member in addition to proband with early-onset
cancer is extremely rare. In breast cancer, 98% of the families
with an early-onset proband had no other familial early-onset
breast cancers and the proportion was even larger for all other
studied cancers. The cumulative risk of familial cancer by age
41 was highest for breast cancer among offspring (1.63%) and
siblings (2.05%) of the proband. This implies that early-onset
breast cancer among offspring and siblings of the proband is
very rare event. All studied cancers, except melanoma, showed
signiﬁcant variation in the familial relative risks between ﬁrst-
degree relatives and spouses. The familial relative risk for early-
onset cancer was the highest among the ﬁrst-degree relatives of
colorectal cancer probands (SIR of father of the proband 20)
and lowest in skin melanoma (none cases among mothers of
the proband and some twofold risks in other ﬁrst-degree rela-
tives). SIRs of the siblings in the multiplex families were very
high for cancers of the colorectum (90) and CNS (29), while in
multiplex breast cancer families the SIR was lower (10).
Strengths of the study
Early-onset cancer is commonly considered an indication of
inherited genetic factors or early exposure to carcinogens. Our
prospective family-based cohort design with exclusively early-
onset probands is powerful in identifying novel familial aggre-
gation. Also, owing to broader inclusion of extended family
members (spouses and siblings’ offspring), the data are likely to
be more powerful than many studies restricted to particular
genetic relationships, such as those with twins or selected nuclear
families. These reasons could explain our higher familial risks
(a) (b)
(c) (d)
Figure 1. Cumulative risk of cancers of CNS, breast, colorectum and melanoma by age 41 years for offspring and siblings of the early-onset
probands and the population. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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than those found in the Nordic twin studies.18 Completeness
and accuracy of cancer information at the FCR have been shown
to be high.15 It provides close to complete national cancer data
for solid tumors. We have also complete information on can-
cers of relatives based on registry-linkage. The SIR-based
method we used is considered reliable, as the statistical analyses
adjust for both ascertainment and immortal bias, and the used
Poisson excess risk model accounts for censoring in time-
to-event analysis. The method also adjusts for changes in popula-
tion cancer risk by calendar time, age and sex. The conventional
way of estimating SIR provides as stable estimates as possible for
expected numbers of cancers by utilizing cancer incidence rates
of the whole target population as the reference. The reported SIR
may, to some extent, underestimate the relative risks between the
exposed and unexposed, leading to conservative conclusions. As
the early-onset familial cancers are extremely rare events and
exposure to early-onset family history of cancer is rare as well,
the potential bias is, however, likely to be small.
Inclusion of probands’ and their siblings’ spouses and sib-
lings’ offspring enables better contrasting of the environmen-
tal and genetic inﬂuence on cancer risk. Spouses are unrelated
to the probands and should reﬂect population cancer risk if
there is no shared environmental effect with the proband. Sib-
lings’ offspring are also informative as they share only 25% of
the genetic background with the proband.
Limitations of the study
A shortcoming of our ascertainment scheme is that follow-up
for late-onset cancers in family members remains rather short
and comparison of relative risks between early- and late-onset
familial cancers would gain more power with a longer follow-
up. Second, in the current analysis, we have no systematic
information on the inherited cancer syndromes or gene muta-
tions inﬂuencing cancer risks, such as FAP and HNPCC for
colorectal cancer, NF for CNS cancers or BRCA1 or BRCA2
for breast cancer. Overall, FAP is estimated to account for less
than 1% and HNPCC for some 3% of all colorectal cancer
cases.19,20 As for breast cancer, Peto et al.21 reported that 6%
of the women diagnosed with early-onset breast cancer were
carriers of BRCA1 and BRCA2 gene mutations. It is also well
established that the risk of CNS cancer is majorly increased in
patients with NF.22
To narrow down the problem of known inherited cancer syn-
dromes or gene mutations in the analyses, we extracted informa-
tion on FAP, HNPCC, NF and BRCA 1/2 mutations from cancer
notiﬁcations available at the FCR. This was focused on multiplex
families with concordant primary cancers since these would most
likely be explained by known inherited mutations. All multiplex
CNS families and 40% of the multiplex colorectal cancer families
were found to belong to families with either NF or FAP/HNPCC
syndrome. We found no information on BRCA 1/2 mutations in
multiplex breast cancer families, but it should be noted that data
on these mutations at the FCR are incoherent.
Lower fertility among early-onset cancer subjects may lead
to observing more healthy family members and thus under-
estimating the cancer burden in these families.23 Also, higher
mortality of early-onset cancer patients before reproduction
may lead to selection of early-onset cases.
Table 3. Numbers of family members of the proband, number of observed cancer cases and standardized incidence ratios (SIR) for early-onset
(≤40 years) concordant cancer in siblings of the proband by concordant parental cancer at any age
Relatedness to the proband
Number of family
members of the
proband
Number of
cancers Person-years
SIR for concordant
cancer1 (95% CI)
Brain and other CNS cancers2
Sibling with affected parent3 194 6 3,954 29 (11–64)
Sibling without affected parent4 10,458 18 196,353 1.80 (1.06–2.84)
Breast cancer2
Sibling with affected parent3 980 10 15,226 10 (4.85–19)
Sibling without affected parent4 8,513 33 137,842 4.14 (2.85–5.81)
Colorectal cancer2
Sibling with affected parent3 363 10 6,405 905 (43–165)
Sibling without affected parent4 3,392 6 59,233 5.29 (1.94–12)
Melanoma2
Sibling with affected parent3 193 0 3,414 0.00 (0.00–30)
Sibling without affected parent4 5,145 7 84,220 2.23 (0.90–4.60)
1SIR (95% CI) for concordant cancer in the family member of the proband.
2According to pathological reports retrieved from the Finnish Cancer Registry for siblings with affected parents, all brain and CNS cases were in families
with neurofibromatosis in at least one subjects with diagnosed cancer. We found no record of BRCA carriers among breast cancer probands and their
siblings or parents. FAP or HNPCC was found in four of the 10 multiplex colorectal cancer families.
3At least one sibling diagnosed with the concordant cancer at age ≤40 years and at least either one of the parents diagnosed with the concordant cancer
at any age. There were no families with both affected parents.
4At least one sibling diagnosed with the concordant cancer at age ≤40 years, no parents with concordant cancer.
5SIR for the families without FAP or HNPCC was 56 (21–122).
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As our study was registry-based, we could not adjust the ana-
lyses for known environmental risk factors, such as for ultraviolet
radiation in the analyses of melanoma risks, or for age at menar-
che in breast cancer analyses. However, despite some studies,24
there is no convincing evidence of risk factors other than family
history and cancer syndromes in early-onset colorectal cancer
and CNS cancers, making the current analyses more valid for
these cancers.
Due to the rare nature of early-onset familial cancers, it
would be natural and fruitful to collaborate with other large
population-based genetic-epidemiological familial studies such
as the Swedish Family Cancer Database.9 This would increase
the number of familial cancers and the ability to detect novel
familial aggregation.
How do the current ﬁndings relate to previous knowledge?
To the best of our knowledge, this is the ﬁrst time, when
familial relative risks and cumulative risks for early-onset can-
cers are reported from a comprehensive population-based reg-
istry. Majority of the previous studies of early-onset cancer
families are based on clinical or hospital-based sets of families.
We observed considerably higher sibling risk for early-onset
CNS cancer than studies from the Swedish Family Cancer
Database,10,25 especially when also the parent was diagnosed
with the concordant cancer (SIR 29). Dong and Hemminki
reported from the Swedish data a SIR of 11 for nervous system
cancers when both the parent and the sibling were affected.10
Overall, the analysis of the Utah family data found a relative
risk (RR) of 6.4 for astrocytoma and glioblastoma for ﬁrst-
degree relatives with onset at <20 years of age,26 whereas we
obtained a SIR 2.50 for CNS cancer in ﬁrst-degree relatives
diagnosed at ≤40 years. In our study, all familial cases of CNS
cancers in multiplex families were those with NF.
We observed a SIR of 3.67 for early-onset breast cancer in
ﬁrst-degree relatives, whereas Frank et al. reported RR 2.15
for ﬁrst-degree relatives of a proband diagnosed at <60 years25
and Althuis et al. observed RR of 3.22 for families with family
history of breast cancer in adolescents and young adults
(<35 years).27 However, our SIR for early-onset breast cancer
of siblings in multiplex families (10) is substantially higher
than the RR reported by Frank et al. (2.88).25 The difference
can be at least partly due to our families ascertained at a
younger age. Our result is, however, in line with the risk ratio
of 14 presented by the Collaborative Group on Hormonal Fac-
tors in Breast Cancer for women with two ﬁrst-degree rela-
tives with a history of breast cancer, with at least one of them
diagnosed before the age 40 years.28
Compared to Frank et al.,25 a stronger age-at-onset effect
of familial colorectal cancer was detected for ﬁrst-degree rela-
tives in our study. Our SIR was 2.11 for cases diagnosed at
≥41 years and 14 for diagnoses at ≤40 years, compared to RR
1.80 for familial cases at ≥60 years of age and 3.14 for diagno-
ses at <60 years reported by Frank et al.25 SIR for colorectal
cancer in siblings with a concordant parental cancer in our
study was 90, which is much higher than the SIRs observed
by Dong and Hemminki for families with affected parent and
sibling (28 for colon and 33 for rectum).10 We found only two
cases of FAP and two cases of HNPCC out of 10 colorectal
cancers among siblings in the multiplex families, based on
clinical notiﬁcations from the FCR.
Cumulative risk for melanoma of the skin by the age of
41 was modest (0.3%) for proband’s siblings and offspring
and was at the population level. This is different from that
reported by Fallah et al.,12 who reported a lifetime risk of 3%
for family members of a melanoma case diagnosed under the
age 30. The difference is probably mainly because we only
estimated cumulative risk until the age of 41. In melanoma of
the skin, familial SIR did not change signiﬁcantly by age-at-
onset of the familial case, while Frank et al. observed RR 3.13
for early-onset familial cancers (diagnosed at <60 years of age)
and 2.19 for cases diagnosed at ≥60 years. Notably, there were
no early-onset cases of melanoma in our data among 193 sib-
lings with parental skin melanoma.
The observed familial risks were higher throughout in fam-
ily members with early-onset diagnosis, compared to those
with late-onset cancers. Considering that our probands were
all ≤40 years of age, the ﬁnding supports the dual age effect,
where both the probands’ as well as the family members’ age
at diagnosis affect the risk of familial cancer. The observation
is also supported by Kharazmi et al., who found in their study
that familial cancers are likely to be early-onset mainly in per-
sons, whose family members are affected at early ages and not
in those whose family members were affected at older ages.11
Public health point of view
The prospective follow-up of the family cohort enables esti-
mation of cumulative risks until the age of ≤41 for siblings
and offspring of early-onset cancer patients. From the public
health point of view, early-onset cancers studied here are rare
with the highest population cumulative risk in early-onset
breast cancer (0.56%) and cumulative risk of 2.05% for sib-
lings of the proband. It should be noted that in all studied
cancers 98% or more of the cases were sporadic, that is, there
was no other family member with a concordant early-onset
cancer. The observed relative and cumulative risks should be
informed to young (≤40 years) relatives of early-onset cancer
patients in a balanced manner. Despite the large familial rela-
tive risks for family members of early-onset cancer cases, the
relatives should be made aware of the modest cumulative
risks. However, in case additional information about known
familial cancer syndromes or cancer-predisposing mutations
is available, the risk should be assessed taking the carrier sta-
tus into account.
The generalizability of our ﬁndings depends on to what
extent etiological factors (genetic or environmental) concerning
early-onset cancers differ between the countries. Finns are often
considered genetically different by population history and foun-
der effects, but such an effect would have to be large in order to
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explain a substantial fraction of early-onset cancer cases that are
not already explained by known inherited mutations or syn-
dromes. Furthermore, we did not ﬁnd substantially different can-
cer incidence trends among early-onset cancers between the
Nordic countries, implicating against substantial founder effects.
Since little is known about causal risk factors of early-onset can-
cers, it is difﬁcult to speculate their role in extrapolation of our
ﬁndings to other countries.
In summary
The familial relative risks in siblings of the proband differed
greatly by the parental cancer status in early-onset cancers of
the colorectum and CNS and less so in breast cancer, imply-
ing a major role of inherited factors in the etiologies of colo-
rectal and CNS cancers in multiplex families. Likewise, the
increased SIRs in siblings’ offspring in CNS and colorectal
cancers provide further evidence for a genetic inﬂuence,
whereas in breast cancer the respective SIRs were at population
level. This combined with smaller observed effects in breast
cancer, compared to colorectal and CNS cancers when stratify-
ing by parental cancer status, suggests either an important role
of environmental factors or a set of rare genetic factors in
causation of early-onset breast cancer. Considering the notably
high dual age effect in familial risk of colorectal cancer in sib-
lings in multiplex families, and as only a small proportion of
the effect was explained by FAP or HNPCC, other known or
unknown inherited mutations are plausible in these families.
Combining our ﬁndings with previous reports on the preva-
lence of BRCA1 and BRCA2 mutations in early-onset breast
cancer (5.9%21) and approximately 10% of other germline
predisposing mutations in breast cancer patients at any age,29 it
is likely that environmental factors play a large role in early-
onset breast cancer.
In conclusion, early-onset cancers are mainly sporadic.
Our ﬁndings support high familial aggregation in early-onset
CNS and colorectal cancers. Familial aggregation in multiplex
families with CNS cancers was mainly attributed to NF and in
colorectal cancer to FAP and HNPCC. The pattern of familial
aggregation of early-onset breast cancer could be seen to sup-
port both very early exposure to environmental factors and/or
rare genetic factors.
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